Nutriband Inc. (NASDAQ: NTRB) announced that Chief Executive Officer Gareth Sheridan has published a letter to shareholders outlining key achievements during 2025 and providing perspective on the company's priorities and outlook for 2026. The update highlighted Nutriband's continued focus on shareholder value, including disciplined capital management, a 25% preferred stock dividend issued in 2025, and progress toward reducing share price volatility with the expiration of IPO-era warrants in October 2026.
The company detailed significant advances for its lead product, AVERSA(TM) Fentanyl, which is being developed as an abuse-deterrent opioid transdermal patch. During 2025, Nutriband strengthened its intellectual property portfolio with new U.S. patent issuances, completed commercial manufacturing scale-up, and received FDA feedback through a Type C meeting to support its regulatory pathway. Additional milestones included inclusion in four Russell indexes and strategic transactions intended to support long-term growth as the company continues advancing AVERSA(TM) Fentanyl toward commercialization.
Nutriband is primarily engaged in the development of a portfolio of transdermal pharmaceutical products. The company's lead product under development is an abuse-deterrent fentanyl patch incorporating AVERSA(TM) abuse-deterrent technology. This technology can be incorporated into any transdermal patch to prevent the abuse, misuse, diversion, and accidental exposure of drugs with abuse potential. The company's website is https://www.nutriband.com.
The announcement carries significant implications for the pharmaceutical industry and public health. The development of abuse-deterrent opioid formulations represents a critical response to the ongoing opioid crisis, which continues to claim thousands of lives annually. Nutriband's progress with AVERSA(TM) Fentanyl could potentially offer healthcare providers a safer alternative for managing severe pain while reducing the risk of diversion and abuse that has plagued traditional opioid formulations.
For investors, the company's disciplined capital management approach and strategic milestones suggest a measured path toward commercialization. The 25% preferred stock dividend issued in 2025 demonstrates the company's commitment to shareholder returns even during the development phase. The expiration of IPO-era warrants in October 2026 could potentially reduce share price volatility, providing more stability for long-term investors as the company approaches key regulatory milestones.
The FDA feedback received through a Type C meeting represents a significant regulatory milestone, providing the company with clearer guidance on its path toward potential approval. This regulatory progress, combined with completed commercial manufacturing scale-up, positions Nutriband to potentially accelerate its timeline toward bringing AVERSA(TM) Fentanyl to market. The company's inclusion in four Russell indexes also enhances its visibility within the investment community, potentially broadening its investor base as it advances toward commercialization.
The latest news and updates relating to NTRB are available in the company's newsroom at https://nnw.fm/NTRB. The full press release can be viewed at https://nnw.fm/kjl5j.
